|
|
Blood, 1 July 2005, Vol. 106, No. 1, pp. 125-134.
Prepublished online as a Blood First Edition Paper on March 1, 2005; DOI 10.1182/blood-2004-09-3679.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
Takeshi Yabu,
Hidekazu Tomimoto,
Yoshimitsu Taguchi,
Shohei Yamaoka,
Yasuyuki Igarashi, and
Toshiro Okazaki
From the Department of Hematology/Oncology and the Department of Neurology, Graduate School of Medicine, Kyoto University, Japan; the Department of Biomembrane and Biofunctional Chemistry, Graduate School of Pharmaceutics, Hokkaido University, Sapporo, Japan; and the Department of Hematology/Clinical Laboratory Medicine, School of Medicine, Tottori University, Yonago City, Tottori, Japan.
Thalidomide, which is clinically recognized as an efficient therapeutic agent for multiple myeloma, has been thought to exert antiangiogenic action through an unknown mechanism. We here show a novel mechanism of thalidomide-induced antiangiogenesis in zebrafish embryos. Thalidomide induces the defect of major blood vessels, which is demonstrated by their morphologic loss and confirmed by the depletion of vascular endothelial growth factor (VEGF) receptors such as neuropilin-1 and Flk-1. Transient increase of ceramide content through activation of neutral sphingomyelinase (nSMase) precedes thalidomide-induced vascular defect in the embryos. Synthetic cell permeable ceramide, N-acetylsphingosine (C2-ceramide) inhibits embryonic angiogenesis as well as thalidomide. The blockade of ceramide generation by antisense morpholino oligonucleotides for nSMase prevents thalidomide-induced ceramide generation and vascular defect. In contrast to ceramide, sphingosine-1-phosphate (S1P) inhibits nSMase-dependent ceramide generation and restores thalidomide-induced embryonic vascular defect with an increase of expression of VEGF receptors. In human umbilical vein endothelial cells (HUVECs), thalidomide-induced inhibition of cell growth, generation of ceramide through nSMase, and depletion of VEGF receptors are restored to the control levels by pretreatment with S1P. These results suggest that thalidomide-induced antiangiogenic action is regulated by the balance between ceramide and S1P signal.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Yabu, A. Shimuzu, and M. Yamashita
A Novel Mitochondrial Sphingomyelinase in Zebrafish Cells
J. Biol. Chem.,
July 24, 2009;
284(30):
20349 - 20363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Johnson, S. Corthals, C. Ramos, A. Hoering, K. Cocks, N. J. Dickens, J. Haessler, H. Goldschmidt, J. A. Child, S. E. Bell, et al.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Blood,
December 15, 2008;
112(13):
4924 - 4934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yabu, S. Imamura, M. Yamashita, and T. Okazaki
Identification of Mg2+-dependent Neutral Sphingomyelinase 1 as a Mediator of Heat Stress-induced Ceramide Generation and Apoptosis
J. Biol. Chem.,
October 31, 2008;
283(44):
29971 - 29982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rubegni, S. Poggiali, R. Bilenchi, A. Diana, M. Risulo, L. Civeli, and M. Fimiani
Venous Ulcers of the Lower Limbs Due to Congenital Thalidomide-Related Valve Defect
Angiology,
September 1, 2007;
58(4):
491 - 493.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Mannheim, D. Versari, E. Daghini, M. Gossl, O. Galili, A. Chade, V. S. Rajkumar, E. L. Ritman, L. O. Lerman, and A. Lerman
Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization
Am J Physiol Heart Circ Physiol,
May 1, 2007;
292(5):
H2449 - H2458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Chidlow Jr., W. Langston, J. J.M. Greer, D. Ostanin, M. Abdelbaqi, J. Houghton, A. Senthilkumar, D. Shukla, A. P. Mazar, M. B. Grisham, et al.
Differential Angiogenic Regulation of Experimental Colitis
Am. J. Pathol.,
December 1, 2006;
169(6):
2014 - 2030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shalapour, A. Zelmer, M. Pfau, E. Moderegger, C. Costa-Blechschmidt, F. K.H. van Landeghem, T. Taube, I. Fichtner, C. Buhrer, G. Henze, et al.
The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5526 - 5532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gulbins and P. L. Li
Physiological and pathophysiological aspects of ceramide
Am J Physiol Regulatory Integrative Comp Physiol,
January 1, 2006;
290(1):
R11 - R26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
